These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 26452232)

  • 41. Changes in erythropoiesis-stimulating agent (ESA) dosing and haemoglobin levels in US non-dialysis chronic kidney disease patients between 2005 and 2009.
    Regidor D; McClellan WM; Kewalramani R; Sharma A; Bradbury BD
    Nephrol Dial Transplant; 2011 May; 26(5):1583-91. PubMed ID: 20861195
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment with high dose of erythropoiesis-stimulating agents and mortality: analysis with a sequential Cox approach and a marginal structural model.
    Suttorp MM; Hoekstra T; Mittelman M; Ott I; Krediet RT; Dekker FW; Putter H
    Pharmacoepidemiol Drug Saf; 2015 Oct; 24(10):1068-75. PubMed ID: 26265483
    [TBL] [Abstract][Full Text] [Related]  

  • 43. High Hemoglobin Levels Maintained by an Erythropoiesis-Stimulating Agent Improve Renal Survival in Patients with Severe Renal Impairment.
    Tsubakihara Y; Akizawa T; Iwasaki M; Shimazaki R
    Ther Apher Dial; 2015 Oct; 19(5):457-65. PubMed ID: 25944732
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Should we adjust erythropoiesis-stimulating agent dosage to postdialysis hemoglobin levels? A pilot study.
    Castillo N; García-García P; Rivero A; Jiménez-Sosa A; Macía M; Getino MA; Méndez ML; García-Pérez J; Navarro-González JF
    BMC Nephrol; 2012 Jul; 13():60. PubMed ID: 22799577
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Parathyroidectomy Improves the Consumption of Erythropoiesis-Stimulating Agents in Hemodialysis Patients.
    Lee YT; Tu CW; Kam KH; Ma TL; Kuo CH; Lee MY; Hsiao CY; Chan MWY; Hung PH
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142295
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Erythropoiesis-stimulating agents: dose and mortality risk.
    Bellinghieri G; Condemi CG; Saitta S; Trifirò G; Gangemi S; Savica V; Buemi M; Santoro D
    J Ren Nutr; 2015 Mar; 25(2):164-8. PubMed ID: 25529282
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy.
    Mohanram A; Zhang Z; Shahinfar S; Keane WF; Brenner BM; Toto RD
    Kidney Int; 2004 Sep; 66(3):1131-8. PubMed ID: 15327408
    [TBL] [Abstract][Full Text] [Related]  

  • 48. High target hemoglobin with erythropoiesis-stimulating agents has advantages in the renal function of non-dialysis chronic kidney disease patients.
    Tsubakihara Y; Gejyo F; Nishi S; Iino Y; Watanabe Y; Suzuki M; Saito A; Akiba T; Hirakata H; Akizawa T
    Ther Apher Dial; 2012 Dec; 16(6):529-40. PubMed ID: 23190512
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Higher doses of erythropoietin-stimulating agents and hyporesponsiveness to their effects are associated with increased mortality among prevalent hemodialysis patients.
    Nishio A; Chhatkuli BP; Ma JZ; Kalantari K
    Blood Purif; 2013; 36(1):29-36. PubMed ID: 23735569
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Testosterone deficiency is a cause of anaemia and reduced responsiveness to erythropoiesis-stimulating agents in men with chronic kidney disease.
    Carrero JJ; Bárány P; Yilmaz MI; Qureshi AR; Sonmez A; Heimbürger O; Ozgurtas T; Yenicesu M; Lindholm B; Stenvinkel P
    Nephrol Dial Transplant; 2012 Feb; 27(2):709-15. PubMed ID: 21617198
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Erythropoiesis-stimulating agent resistance and mortality in hemodialysis and peritoneal dialysis patients.
    Suttorp MM; Hoekstra T; Rotmans JI; Ott I; Mittelman M; Krediet RT; Dekker FW
    BMC Nephrol; 2013 Sep; 14():200. PubMed ID: 24066978
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hemoglobin level and risk of hospitalization and mortality in children on peritoneal dialysis.
    Dahlinghaus EK; Neu AM; Atkinson MA; Fadrowski JJ
    Pediatr Nephrol; 2014 Dec; 29(12):2387-94. PubMed ID: 25108709
    [TBL] [Abstract][Full Text] [Related]  

  • 53. An economic evaluation of erythropoiesis-stimulating agents in CKD.
    Clement FM; Klarenbach S; Tonelli M; Wiebe N; Hemmelgarn B; Manns BJ
    Am J Kidney Dis; 2010 Dec; 56(6):1050-61. PubMed ID: 20932621
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mortality associated with dose response of erythropoiesis-stimulating agents in hemodialysis versus peritoneal dialysis patients.
    Duong U; Kalantar-Zadeh K; Molnar MZ; Zaritsky JJ; Teitelbaum I; Kovesdy CP; Mehrotra R
    Am J Nephrol; 2012; 35(2):198-208. PubMed ID: 22286821
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hemoglobin level variability in renal transplant patients treated with erythropoiesis stimulating agents.
    Fernández Fresnedo G; de Francisco AL; Ruiz JC; Gómez Alamillo C; Arias M
    Transplant Proc; 2008 Nov; 40(9):2919-21. PubMed ID: 19010147
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A vitamin E-coated polysulfone membrane reduces serum levels of inflammatory markers and resistance to erythropoietin-stimulating agents in hemodialysis patients: results of a randomized cross-over multicenter trial.
    Panichi V; Rosati A; Paoletti S; Ferrandello P; Migliori M; Beati S; Bernabini G; Daini R; Casani A; Angelini D; Parrini M; Rossi A; Petrone I; Barsotti G; Donadio C; Donati G; Grazi G; Manca Rizza G; Garosi G; Sansoni E; Braccagni B; Sidoti A; Boracelli D; Biagioli M; Moriconi L; Finato V; Mannarino A; Grimaldi C; Pansa F; Imperiali P; Mura C; Bianchi S; Bigazzi R
    Blood Purif; 2011; 32(1):7-14. PubMed ID: 21242686
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of the dose of erythropoiesis stimulating agents on cardiovascular events, quality of life, and health-related costs in hemodialysis patients: the clinical evaluation of the dose of erythropoietins (C.E. DOSE) trial protocol.
    Strippoli GF;
    Trials; 2010 Jun; 11():70. PubMed ID: 20534124
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Low levels of serum ferritin lead to adequate hemoglobin levels and good survival in hemodialysis patients.
    Ogawa C; Tsuchiya K; Kanda F; Maeda T
    Am J Nephrol; 2014; 40(6):561-70. PubMed ID: 25592750
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Erythropoiesis-stimulating agents and thrombotic events in dialysis patients.
    Suttorp MM; Hoekstra T; Ocak G; van Diepen AT; Ott I; Mittelman M; Rabelink TJ; Krediet RT; Dekker FW
    Thromb Res; 2014 Nov; 134(5):1081-6. PubMed ID: 25242244
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of a More Permeable Dialysis Membrane on ESA Resistance in Hemodialysis Patients--A Pilot Investigation.
    Teatini U; Liebchen A; Nilsson LG; Beck W; Longhena GR
    Blood Purif; 2016; 41(1-3):80-6. PubMed ID: 26536083
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.